about
Spanish consensus on the prevention and treatment of Pseudomonas aeruginosa bronchial infections in cystic fibrosis patientsAssessing the residual CFTR gene expression in human nasal epithelium cells bearing CFTR splicing mutations causing cystic fibrosis.Delayed cutaneous hypersensitivity tests and lymphopenia as activity markers in sarcoidosis.GUSB and ATP2B4 are suitable reference genes for CFTR gene expression data normalization in nasal epithelium cells.Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis.Genotype-phenotype correlation for pulmonary function in cystic fibrosis.Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.Controlled trial of intravenous corticosteroids in severe acute asthma.Clinical impact of chronic obstructive pulmonary disease on non-cystic fibrosis bronchiectasis. A study on 1,790 patients from the Spanish Bronchiectasis Historical Registry.Predicting high risk of exacerbations in bronchiectasis: the E-FACED score.Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice.Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective.Multicenter study for the evaluation of the antibody response against salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency.Antibiotic resistance and population structure of cystic fibrosis Pseudomonas aeruginosa isolates from a Spanish multi-centre study.Bronchiectasis: a retrospective study of clinical and aetiological investigation in a general respiratory department.Clinical picture and treatment of 2212 patients with common variable immunodeficiency.Pulmonary disease caused by Mycobacterium gordonae.A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin.Antibody deficiency in bronchiectasis.[The future of inhaled antibiotic therapy. New products].Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score.Herpetic tracheitis and polybacterial pneumonia in an immunocompetent young man is herpes tracheitis involved in the pathogenesis of bacterial pneumonia?Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis.Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial.A new BAL fluid instillation and aspiration technique: a multicenter randomized study.Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.The annual prognostic ability of FACED and E-FACED scores to predict mortality in patients with bronchiectasis.Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.The Multiple Faces of Non-Cystic Fibrosis Bronchiectasis. A Cluster Analysis Approach.Common variable immunodeficiency: association between memory B cells and lung diseases.Elevated serum interleukin (IL)-12p40 levels in common variable immunodeficiency disease and decreased peripheral blood dendritic cells: analysis of IL-12p40 and interferon-gamma gene.Detection of Bacteriophage Particles Containing Antibiotic Resistance Genes in the Sputum of Cystic Fibrosis Patients.Increased risk of tuberculosis transmission in families with microepidemicsSerum immunoglobulins in the infected and convalescent phases in community-acquired pneumoniaAntibody Production Deficiency With Normal IgG Levels in Bronchiectasis of Unknown EtiologySpecific Antibody Response Against the 23-Valent Pneumococcal Vaccine in Patients With α1-Antitrypsin Deficiency With and Without BronchiectasisPrimary immunodeficiency diseases in lung disease: warning signs, diagnosis and managementAntibióticos nebulizados en pacientes con fibrosis quísticaRole of TNFRSF13B variants in patients with common variable immunodeficiencyDiagnósticos y procedimientos en 500 pacientes consecutivos con sospecha clínica de enfermedad pulmonar intersticial
P50
Q26822417-4A92BDE3-56C9-4802-A5D5-721F9769CF80Q33620824-5113E3C1-85D5-4538-B5B2-D2F13358FFD2Q34123259-C7433FF0-5057-4C20-AFAB-109BC2D4B7C3Q34242290-3AB33CF9-10F8-48C9-8E9B-024C50ED2C56Q35426622-AA9949FD-FD63-44FD-A540-7532A2C9AE9AQ35537817-1C1DC0FE-B7A9-4861-9087-26BF8E05D2F3Q36232237-0D82CEFE-09C0-4063-BB12-C2C26C561AC9Q36264362-2A57A739-EAFA-4F27-B55C-C14A8D393F8CQ36380278-B52EAEE1-060E-4313-9F25-85E4BE36D21DQ37613743-F839067C-8E58-4B0A-A7DF-CF901FF3081BQ38360133-280F2B47-2886-47A4-ADF7-974EEE12D0ADQ39517012-0A37A934-DC73-47FF-AFB5-4701412E8E9CQ40103690-0A322431-BFE1-4947-B344-3E9F68476169Q42011000-96B30D89-8E68-4942-B232-D7CAE0EE5DAFQ42174403-36CB5E63-11CE-4C76-A289-C394F103D0E8Q42226474-DA5A8980-A870-414B-902D-13CA83552701Q43626310-EDA5F2BA-769E-4278-9BC2-1C6D6B7B66CBQ43654329-1D508936-1A0F-48FD-93A4-5DE4C0057942Q44157076-3A0D9F3F-DA26-419C-8A28-E0529258FB21Q44624962-3D963ED6-536A-41C4-A4CB-9ED1FF38DB87Q46049767-AE7A8CD3-8D72-4C90-9D50-4028D2EE46BEQ46870243-ADB583D2-BA82-4F50-9AA1-F335EC629375Q47143886-D1485DB0-C5A2-4CE4-B9A9-1073E90ABC2DQ47659147-B227A31F-9053-4899-8964-A029DD3A89BDQ47762810-72879484-7B01-47CE-8D6E-F619820BBAA9Q48034796-6C2C922F-15E4-4F61-943A-49DF8C622623Q50532047-EF6B3652-F4D9-42AE-BDBC-EAFED33EB78CQ51025072-8F129D34-2D0E-48BA-B3B7-7992FF95631EQ51501039-BCF6C162-FCE6-4741-8B32-1AC8225257C3Q51976524-BD051D9F-6361-4234-B4A1-1411ED15B1E5Q54277726-C7BFBDFB-AAEF-49C3-B322-E3E2BBE74A8DQ55373289-9A5A3D18-82DF-4F0E-8F5E-78F6B92EE0EDQ56762839-6D9005F2-3277-42D4-9AFF-EB8673CA5C09Q57237717-AA66723E-5154-4B4E-9DFB-002C62324992Q57778257-300D10AC-CAA0-451F-B08F-DB742A527971Q57778547-2D848ED4-55A0-45C8-95A2-E10C984734F3Q59127411-F0FFFED5-D554-45E7-BEE0-EDB70B13331DQ61479588-608099BA-2FE8-4CC3-BC99-EC789D15F6EFQ62658641-60C54E37-18BB-4A1F-8604-02161AD01BCFQ64134600-D2BD4DD0-48EB-4C04-B4F0-48FD304F078E
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Javier De Gracia
@ast
Javier De Gracia
@en
Javier De Gracia
@es
Javier De Gracia
@nl
Javier De Gracia
@sl
type
label
Javier De Gracia
@ast
Javier De Gracia
@en
Javier De Gracia
@es
Javier De Gracia
@nl
Javier De Gracia
@sl
prefLabel
Javier De Gracia
@ast
Javier De Gracia
@en
Javier De Gracia
@es
Javier De Gracia
@nl
Javier De Gracia
@sl
P108
P214
P106
P1153
55401657800
P21
P214
P31
P496
0000-0003-2830-1991
P735
P7859
viaf-305878650